EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 173 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations August 13, 2018 Teen’s Innovative “SMART Armour” Protects Breast Cancer Patients from Radiation May 31, 2019 With 3 Years Minimum Follow-Up, Nivolumab Plus Ipilimumab Continues to Provide... February 9, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+... October 22, 2020 Load more HOT NEWS FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer Better together: improving brain tumour treatment Jonas Brothers Visit Fan In Hospital Who Missed Their Concert Due... Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas
